Seres Therapeutics, Inc. (MCRB) stock
Close on Nov 12, 2026Market cap $14.02MP/E –Yield –
Seres Therapeutics, Inc. grew revenue 505.4% to $2.13M over the twelve months to Sep 30, 2026. Free cash flow was -$63.97M. At the latest close the market valued the company at $14.02M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $14.02M
- P/E ratio
- –
- Price to sales
- 6.60
- Price to book
- 0.66
- Dividend yield
- –
- Free cash flow yield
- -456.37%
Fundamentals
- Revenue
- $2.13M
- Net income
- -$46.95M
- EPS, diluted
- -$4.90
- Free cash flow
- -$63.97M
- Book value per share
- $2.14
- Diluted shares
- 10M
Trading
- Next earnings
- Mar 11, 2027 (estimated, before the open)
- Previous close
- $1.50
- Open
- $1.48
- Day's range
- $1.30 – $1.48
- Volume
- 74,194
- Average volume (20 days)
- 89,227
- Beta (5 years)
- 0.98
- 52-week range
- $1.30 – $29.98
- RSI (14 days)
- 23.0
- Volatility (1 year)
- 91.6%
- Relative volume
- 0.95×
- WACC
- 9.9%
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | MCRB | S&P 500 | Difference | MCRB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -47.4% | -2.7% | −44.7 pts | ||
| 3 months | -70.1% | -1.7% | −68.4 pts | ||
| Year to date | -90.5% | +11.9% | −102.4 pts | ||
| 1 year | -91.2% | +12.0% | −103.2 pts | ||
| 3 years | -93.1% | +78.2% | −171.2 pts | -58.9% | +21.2% |
| 5 years | -99.1% | +73.2% | −172.3 pts | -60.9% | +11.6% |
| 10 years | -99.4% | +309.6% | −409.1 pts | -40.3% | +15.1% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Seres Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Update
- Update
About Seres Therapeutics
Pharmaceutical Preparations
Seres Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops live biotherapeutic product candidates designed to treat and prevent infections and inflammatory and immune diseases. The company engineers oral consortia of cultivated bacteria to restore gastrointestinal barrier integrity, induce immune homeostasis, and prevent pathogen colonization. Its pipeline includes investigational candidates such as SER-155, which addresses bloodstream infections and immune-related enterocolitis, as well as SER-603 and SER-147 for inflammatory bowel diseases and metabolic conditions. Target populations comprise medically vulnerable patients, including individuals undergoing stem cell transplantation, cancer patients on immune checkpoint inhibitors, and people with chronic liver disease.
Company profile, executives and historySeres Therapeutics stock: common questions
What is Seres Therapeutics's stock price?
MCRB closed at $1.41 on Nov 12, 2026, down 6.00% on the day. Over the past 52 weeks it traded between $1.30 and $29.98.
What is Seres Therapeutics's market cap?
Seres Therapeutics was worth $14.02M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is MCRB's P/E ratio?
Seres Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$4.90), so it has no meaningful P/E ratio.
How much revenue does Seres Therapeutics make?
Seres Therapeutics reported revenue of $2.13M for the twelve months to Sep 30, 2026, up 505.4% from a year earlier.
Does Seres Therapeutics pay a dividend?
No. Seres Therapeutics has not paid a cash dividend over the last twelve months.
When does Seres Therapeutics report earnings next?
Seres Therapeutics is expected to report Q4 FY2026 results on Mar 11, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has MCRB stock performed over the past year?
Including dividends, MCRB returned -91.2% over the past year, against +12.0% for the S&P 500.
How many MCRB shares are sold short?
0M shares were sold short at the latest FINRA report, 3.52% of the float, or 4.3 days of average trading volume.
Who are Seres Therapeutics's competitors?
Companies most similar to Seres Therapeutics by business, industry and size include UPB, STTK, DNTH, XBIO, ORMP.
See a number that looks wrong?